메뉴 건너뛰기




Volumn 1, Issue 2, 2011, Pages 250-258

Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension

Author keywords

Nitric oxide; Pulmonary arterial hypertension; Vasodilator testing; Vasoreactivity

Indexed keywords


EID: 84857844890     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.83449     Document Type: Article
Times cited : (55)

References (26)
  • 1
    • 5344233478 scopus 로고    scopus 로고
    • Pulmonary arterial hypertension
    • Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
    • (2004) N Engl J Med , vol.351 , pp. 1655-1665
    • Farber, H.W.1    Loscalzo, J.2
  • 4
    • 64849109410 scopus 로고    scopus 로고
    • ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
    • McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
    • (2009) J am Coll Cardiol , vol.53 , pp. 1573-1619
    • McLaughlin, V.V.1    Archer, S.L.2    Badesch, D.B.3    Barst, R.J.4    Farber, H.W.5    Lindner, J.R.6
  • 5
    • 3142726157 scopus 로고    scopus 로고
    • Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    • Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
    • (2004) Chest , vol.126 , pp. 35S-62S
    • Badesch, D.B.1    Abman, S.H.2    Ahearn, G.S.3    Barst, R.J.4    McCrory, D.C.5    Simonneau, G.6
  • 6
    • 77349113347 scopus 로고    scopus 로고
    • Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension
    • Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension. Respir Med 2010;104:481-96.
    • (2010) Respir Med , vol.104 , pp. 481-496
    • Tonelli, A.R.1    Alnuaimat, H.2    Mubarak, K.3
  • 7
    • 0026632785 scopus 로고
    • The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
    • Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
    • (1992) N Engl J Med , vol.327 , pp. 76-81
    • Rich, S.1    Kaufmann, E.2    Levy, P.S.3
  • 8
    • 20544448927 scopus 로고    scopus 로고
    • Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension
    • Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11.
    • (2005) Circulation , vol.111 , pp. 3105-3111
    • Sitbon, O.1    Humbert, M.2    Jais, X.3    Ioos, V.4    Hamid, A.M.5    Provencher, S.6
  • 9
    • 0031869664 scopus 로고    scopus 로고
    • Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
    • Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998;12:265-70.
    • (1998) Eur Respir J , vol.12 , pp. 265-270
    • Sitbon, O.1    Humbert, M.2    Jagot, J.L.3    Taravella, O.4    Fartoukh, M.5    Parent, F.6
  • 11
    • 0037126044 scopus 로고    scopus 로고
    • Survival in primary pulmonary hypertension: The impact of epoprostenol therapy
    • McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477-82.
    • (2002) Circulation , vol.106 , pp. 1477-1482
    • McLaughlin, V.V.1    Shillington, A.2    Rich, S.3
  • 12
    • 10044258461 scopus 로고    scopus 로고
    • Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
    • Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78.
    • (2004) Eur Heart J , vol.25 , pp. 2243-2278
    • Galie, N.1    Torbicki, A.2    Barst, R.3    Dartevelle, P.4    Haworth, S.5    Higenbottam, T.6
  • 13
    • 0032576672 scopus 로고    scopus 로고
    • Reduction in pulmonary vascular resistance with long-term epoprostenol (Prostacyclin) therapy in primary pulmonary hypertension
    • McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
    • (1998) N Engl J Med , vol.338 , pp. 273-277
    • McLaughlin, V.V.1    Genthner, D.E.2    Panella, M.M.3    Rich, S.4
  • 14
    • 1342288852 scopus 로고    scopus 로고
    • Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension
    • Morales-Blanhir J, Santos S, de Jover L, Sala E, Paré C, Roca J, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004;98:225-34.
    • (2004) Respir Med , vol.98 , pp. 225-234
    • Morales-Blanhir, J.1    Santos, S.2    De Jover, L.3    Sala, E.4    Paré, C.5    Roca, J.6
  • 15
    • 0032190635 scopus 로고    scopus 로고
    • Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine
    • Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: A safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998;32:1068-73.
    • (1998) J am Coll Cardiol , vol.32 , pp. 1068-1073
    • Ricciardi, M.J.1    Knight, B.P.2    Martinez, F.J.3    Rubenfire, M.4
  • 16
    • 0028888649 scopus 로고
    • Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
    • Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-9.
    • (1995) Am J Respir Crit Care Med , vol.151 , pp. 384-389
    • Sitbon, O.1    Brenot, F.2    Denjean, A.3    Bergeron, A.4    Parent, F.5    Azarian, R.6
  • 17
    • 77951961897 scopus 로고    scopus 로고
    • Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation
    • Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: A reappraisal of the NIH risk stratification equation. Eur Respir J;35:1079-87.
    • Eur Respir J , vol.35 , pp. 1079-1087
    • Thenappan, T.1    Shah, S.J.2    Rich, S.3    Tian, L.4    Archer, S.L.5    Gomberg-Maitland, M.6
  • 18
    • 77954759389 scopus 로고    scopus 로고
    • Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
    • Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72.
    • (2010) Circulation , vol.122 , pp. 164-172
    • Benza, R.L.1    Miller, D.P.2    Gomberg-Maitland, M.3    Frantz, R.P.4    Foreman, A.J.5    Coffey, C.S.6
  • 19
    • 0021828193 scopus 로고
    • The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension
    • Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation 1985;71:1191-6.
    • (1985) Circulation , vol.71 , pp. 1191-1196
    • Rich, S.1    Brundage, B.H.2    Levy, P.S.3
  • 20
    • 69249119028 scopus 로고    scopus 로고
    • Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
    • Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:1354-60.
    • (2009) Eur Respir J , vol.33 , pp. 1354-1360
    • Jing, Z.C.1    Jiang, X.2    Han, Z.Y.3    Xu, X.Q.4    Wang, Y.5    Wu, Y.6
  • 21
    • 0030024879 scopus 로고    scopus 로고
    • Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension
    • Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-8.
    • (1996) Circulation , vol.93 , pp. 484-488
    • Raffy, O.1    Azarian, R.2    Brenot, F.3    Parent, F.4    Sitbon, O.5    Petitpretz, P.6
  • 23
    • 62249199804 scopus 로고    scopus 로고
    • Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006
    • Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-7.
    • (2009) Heart , vol.95 , pp. 312-317
    • Haworth, S.G.1    Hislop, A.A.2
  • 24
    • 0033662278 scopus 로고    scopus 로고
    • Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology
    • Krasuski RA, Warner JJ, Wang A, Harrison JK, Tapson VF, Bashore TM. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000;36:2204-11.
    • (2000) J am Coll Cardiol , vol.36 , pp. 2204-2211
    • Krasuski, R.A.1    Warner, J.J.2    Wang, A.3    Harrison, J.K.4    Tapson, V.F.5    Bashore, T.M.6
  • 25
    • 0033782458 scopus 로고    scopus 로고
    • Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension
    • Strange C, Bolster M, Mazur J, Taylor M, Gossage JR, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000;118:1077-82.
    • (2000) Chest , vol.118 , pp. 1077-1082
    • Strange, C.1    Bolster, M.2    Mazur, J.3    Taylor, M.4    Gossage, J.R.5    Silver, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.